Global Urinary Tract Infection (UTI) Market Information; by Drug Class (Quinolones, Aminoglycosides, β-lactam, Azoles), by Clinical Indications (Urethritis, Cystitis, Pyelonephritis), by End User (Hospitals, Self-administered) – Forecast to 2023
Urinary Tract Infection (UTI) Market Scenario
Urinary Tract Infection (UTI) is defined as the infection of the lower or upper urinary tract that is caused by bacterial agents like Escherichia coli, Staphylococcus saprophyticus, and others. UTI treatment cures this infection. A new report on the global urinary tract infection (UTI) market, published by Market Research Future (MRFR), assays that this market could notice a hike at 3.6% CAGR between 2019 and 2023. In terms of money value, the market can be worth USD 9.89 Bn by the end of the forecast period.
Get a FREE Sample Copy of Report with Complete TOC @ https://www.marketresearchfuture.com/sample_request/6138
The most important market driving factors for the global urinary tract infection market growth include increasing investment in the healthcare sector, growing use of technology in the healthcare sector, research & development (R&D) in the healthcare sector, and most importantly, the increasing number of patients suffering from UTI. UTI is caused by diabetes, obesity, lack of hygiene, and unsafe intercourse. Due to the inherent complicated female anatomy, UTI infection affects women more than men. However, factors that can hurt the global urinary tract infection (UTI) treatment market growth include growth of drug resistance, loss of patents, and increasing market fragmentation.
Urinary Tract Infection (UTI) Market Key Players
Big players in the global urinary tract infection (UTI) market include
- AstraZeneca (UK)
- Bayer AG (Germany)
- Cipla Inc. (India)
- Dr. Reddy’s Laboratories Ltd. (India)
- GlaxoSmithKline (UK)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Johnson & Johnson (USA)
- Novartis AG (Switzerland)
- Pfizer Inc. (USA)
Urinary Tract Infection (UTI) Market Segmentation
The global urinary tract infection (UTI) market segmentation encompasses clinical indications, drug class, and end-users. MRFR’s take on the market surveys various facets of the market in-depth.
Based on clinical indications, this market has been segmented into cystitis, pyelonephritis, urethritis, and others. Regarding drug class, the market has been segmented into aminoglycosides, azoles, beta-lactam (β-lactam), quinolones, and others. In the context of end-users, the market has been segmented into hospitals, self-administered, and others.
Regional Segmentation
A geographical outlining of the global urinary tract infection (UTI) market covers North America, Europe, Asia Pacific, the Middle East & Africa (MEA), and Rest of the World (RoW).
Lead by the USA; North America holds the maximum market share in the global market followed by Europe. The factors that can boost the UTI treatment market in the USA include the recent regulatory shift in the USA such as the implementation of Affordable Care Act as well as Hospital Readmissions Reduction Program, along with Medicare initiative to penalize unnecessary patient readmissions. After USA, Canada is the strongest economy in this region that can become a strong country-specific market. Many significant market players are based in North America, and patients have high disposable income.
Although the USA spends a lot on healthcare, has a higher hospitalization rate, which makes this region, a crucial regional market due to the high density of population. The strongest economies in this region that can spend more on healthcare and generate higher revenue are France, Germany, and the UK. In these countries, patients have high purchasing power. Many important market players are also based in Europe.
As North America and Europe are developed markets, the growth is stagnant as most people here can afford healthcare. Hence, many market players are exploring Asia Pacific region as a new regional market due to economic growth, infrastructure development, high density of population, and improving the healthcare sector in China and India. During the forecast period, the Asia Pacific region can be the fastest growing regional market which these two countries in the forefront. Due to economic development and technological advancement, Japan can be a powerful country-specific market in this region.
The MEA region is a paltry market due to lack of infrastructure, backward healthcare sector, and lack of skilled professionals. The RoW segment covers South America and other countries that are not in any of the mentioned regional segment. In South America, Argentina and Brazil are two countries that are strong economies. They hold the potential of becoming strong country-specific markets.
Urinary Tract Infection (UTI) Industry News
Biotechnology company LUCA Biologics is working to develop live biotherapeutics for Women’s Health. They are going to start with biotherapeutics that address the health issues caused by UTI. 6 AUG 2019
Get More Information on Urinary Tract Infection (UTI) Market Research Report – Forecast to 2023 @ https://www.marketresearchfuture.com/reports/urinary-tract-infection-market-6138
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Contact:
Akash Anand
Market Research Future
+1 646 845 9312